Literature DB >> 11999352

F-blast is a useful marker for differentiating hypocellular refractory anemia from aplastic anemia.

Jong Weon Choi1, Masahiko Fujino, Masafumi Ito.   

Abstract

Making a morphologic distinction between hypocellular refractory anemia (hypo RA) and aplastic anemia (AA) is difficult. To investigate the significance of hemoglobin F-containing erythroblasts (F-blasts) and p53 expression in making the distinction between hypo RA and acquired AA, we immunohistochemically assessed F-blasts and p53 in bone marrow specimens from 16 patients with hypo RA, 31 patients with acquired AA, and 15 hematologically normal individuals. F-blast production was elevated in 87.5% (14/16) of patients with hypo RA, but in only 3.2% (1/31) of patients with AA (P < .01). p53 was overexpressed in 75.0% (12/16) of hypo RA patients and in 6.4% (2/31) of AA patients (P < .01). The mean contents of F-blasts and p53-positive cells in patients with hypo RA were 6.31% +/- 3.27% and 7.54% +/- 4.36%, respectively, of all bone marrow cells, which were significantly higher than for patients with AA (0.35% +/- 0.46% and 0.58% +/- 1.29%, P < .01). In conclusion, a high prevalence of elevated F-blast production is noted in hypo RA, suggesting that the assessment of F-blasts in bone marrow can be used as an additional tool for differentiating hypo RA from acquired AA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11999352     DOI: 10.1007/bf02982038

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  10 in total

Review 1.  Peripheral blood picture in primary hypocellular refractory anemia and idiopathic acquired aplastic anemia: an additional tool for differential diagnosis.

Authors:  M T Elghetany; S D Hudnall; F H Gardner
Journal:  Haematologica       Date:  1997 Jan-Feb       Impact factor: 9.941

2.  A new anti-hemoglobin F antibody against synthetic peptides for the detection of F-cell precursors (F-blasts) in bone marrow.

Authors:  J W Choi; Y Kim; M Fujino; M Ito
Journal:  Int J Hematol       Date:  2001-10       Impact factor: 2.490

3.  Fetal hemoglobin restriction to a few erythrocytes (F cells) in normal human adults.

Authors:  S H Boyer; T K Belding; L Margolet; A N Noyes
Journal:  Science       Date:  1975-04-25       Impact factor: 47.728

4.  P53 overexpression in bone marrow biopsies in refractory anemia and aplastic anemia: impact of antibody selection.

Authors:  M T Elghetany
Journal:  Leuk Res       Date:  2000-11       Impact factor: 3.156

5.  Study of p53 in elderly patients with myelodysplastic syndromes by immunohistochemistry and DNA analysis.

Authors:  M Kikukawa; N Aoki; Y Sakamoto; M Mori
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

6.  Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.

Authors:  H Kurotaki; Y Tsushima; K Nagai; S Yagihashi
Journal:  Acta Haematol       Date:  2000       Impact factor: 2.195

7.  Aplastic anaemia and the hypocellular myelodysplastic syndrome: histomorphological, diagnostic, and prognostic features.

Authors:  I Fohlmeister; R Fischer; B Mödder; M Rister; H E Schaefer
Journal:  J Clin Pathol       Date:  1985-11       Impact factor: 3.411

8.  Significance of p53 overexpression in bone marrow biopsies from patients with bone marrow failure: aplastic anemia, hypocellular refractory anemia, and hypercellular refractory anemia.

Authors:  M T Elghetany; S Vyas; G Yuoh
Journal:  Ann Hematol       Date:  1998-12       Impact factor: 3.673

9.  Hemoglobin F in myelodysplastic syndrome.

Authors:  D Reinhardt; D Haase; C Schoch; S Wollenweber; E Hinkelmann; W v Heyden; G Lentini; B Wörmann; W Schröter; A Pekrun
Journal:  Ann Hematol       Date:  1998 Mar-Apr       Impact factor: 3.673

Review 10.  Apoptosis in myelodysplasia: a paradox or paradigm.

Authors:  Y Yoshida; N Anzai; H Kawabata
Journal:  Leuk Res       Date:  1995-12       Impact factor: 3.156

  10 in total
  6 in total

Review 1.  Immunologic aspects of hypoplastic myelodysplastic syndrome.

Authors:  Rodrigo T Calado
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

Review 2.  The diagnosis from the pathological viewpoint of a blood disease.

Authors:  Masafumi Ito
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

3.  Clinical Relevance of p53 Immunohistochemical Stain in the Differential Diagnosis Between Pediatric Aplastic Anemia and Refractory Cytopenia of Childhood.

Authors:  Sang Hyuk Park; Hyun-Sook Chi; Young-Uk Cho; Seongsoo Jang; Chan-Jeoung Park; Ho-Joon Im; Jong-Jin Seo
Journal:  Ann Lab Med       Date:  2016-03       Impact factor: 3.464

4.  CD34 and p53 immunohistochemical stains differentiate hypocellular myelodysplastic syndrome (hMDS) from aplastic anemia and a CD34 immunohistochemical stain provides useful survival information for hMDS.

Authors:  Choong-Hwan Cha; Chan-Jeoung Park; Hyun-Sook Chi; Eul Ju Seo; Seongsoo Jang; Young-Uk Cho; Kyoo-Hyung Lee; Je-Hwan Lee; Jung-Hee Lee; Ho Joon Im; Jong-Jin Seo
Journal:  Ann Lab Med       Date:  2014-10-28       Impact factor: 3.464

Review 5.  Hypoplastic Myelodysplastic Syndromes: Just an Overlap Syndrome?

Authors:  Bruno Fattizzo; Fabio Serpenti; Wilma Barcellini; Chiara Caprioli
Journal:  Cancers (Basel)       Date:  2021-01-03       Impact factor: 6.639

6.  Immunological derangement in hypocellular myelodysplastic syndromes.

Authors:  B Serio; Am Risitano; V Giudice; N Montuori; C Selleri
Journal:  Transl Med UniSa       Date:  2014-02-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.